Designation of Thiotepa (Tepadina) as an orphan drug by Helex-A Pty Ltd.

Overview

The Therapeutic Goods Act 1989, enacted by the Commonwealth Parliament, addresses the regulation of therapeutic goods in Australia to ensure their safety, quality, and efficacy. This legislation provides a framework for the control of therapeutic goods, including medicines, medical devices, and blood and blood components. The Act was introduced to address the need for a comprehensive system to regulate therapeutic goods, ensuring they meet necessary standards to protect public health. One of the key policy objectives of the Act is to facilitate access to therapeutic goods that treat rare or orphan conditions, which are often neglected due to their low prevalence. In line with this objective, the Therapeutic Goods Administration, through the Delegate of the Secretary, has the authority to designate certain medicines as orphan drugs, thereby supporting the development and availability of treatments for rare diseases. This specific designation of Thiotepa (TEPADINA) as an orphan drug for the conditioning treatment prior to haematopoietic progenitor cell transplantation exemplifies the Act’s intent to address therapeutic gaps for rare conditions.

Scope and Application

The Therapeutic Goods Act 1989, under the Therapeutic Goods Regulations 1990, designates specific therapeutic goods for particular medical treatments, as evidenced by the designation of Thiotepa (TEPADINA) as an orphan drug for conditioning treatment prior to haematopoietic progenitor cell transplantation. This designation applies to Thiotepa (TEPADINA) in its powder for injection dose form, and it is applicable to the sponsor of the drug, Helex-A Pty Ltd. The scope of this Act extends nationally across the Commonwealth of Australia, governed by the Therapeutic Goods Administration (TGA). This designation is specific to the therapeutic application noted, and no exclusions or exemptions are stated within the provided text. The application of the Act is further extended and detailed through subordinate instruments, such as the Therapeutic Goods Regulations 1990, which provide the legal framework and mechanisms for such designations. This legislative approach ensures that orphan drugs, which are critical for treating rare diseases, receive the necessary regulatory attention and support.

Key Provisions

The Therapeutic Goods Act 1989 (section 16J) allows the designation of certain drugs as orphan drugs, which are intended for the treatment of rare medical conditions. In this instance, Thiotepa (TEPADINA) has been designated as an orphan drug (section 16J) specifically for the conditioning treatment prior to haematopoietic progenitor cell transplantation. The Therapeutic Goods Regulations 1990 (subregulation 16J(2)) provide the framework for such designations, empowering a delegate of the Secretary to make these determinations. The delegate, Dr Anthony Gill, has exercised this authority by designating Thiotepa (TEPADINA) as an orphan drug for this particular use. The obligations imposed by this designation require Helex-A Pty Ltd, the sponsor of Thiotepa (TEPADINA), to ensure that the drug is appropriately registered and available for its specified use. This includes compliance with all relevant therapeutic goods regulations and standards, ensuring that the drug meets the necessary quality, safety, and efficacy requirements. The designation also facilitates certain benefits and incentives, such as priority assessment and reduced regulatory fees, to encourage the development and availability of orphan drugs. Failure to comply with the requirements set out in the Therapeutic Goods Act 1989 and the Therapeutic Goods Regulations 1990 can result in significant consequences. Offences under the Act may lead to both civil and criminal penalties. For example, knowingly supplying a therapeutic good that does not comply with the Act can result in fines up to $330,000 for an individual or $1.65 million for a body corporate, as outlined in section 34(1). Additionally, section 35 imposes a maximum penalty of imprisonment for up to five years for serious or repeated breaches. These stringent penalties underscore the importance of adherence to the legislative requirements to ensure the safety and efficacy of therapeutic goods in Australia.